BEXIMCO PHARMACEUTICALS LTD.

24^th November, 2014

Beximco Pharma Becomes First Bangladeshi Company to
Receive GMP Approval from Health Canada

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has received GMP (Good Manufacturing Practices) approval from the Canadian regulatory authority, Health Canada. Beximco Pharma is the first Bangladeshi company to receive GMP accreditation from Health Canada.

This prestigious and notable achievement opens a new marketing opportunity for Beximco Pharma’s products in the Canadian market and, similar to many other developed countries, Canada is increasingly promoting access to generic drugs, which offers opportunities for generic drug companies like Beximco Pharma. At the beginning of July, Beximco Pharma facilities also received GMP approval from the Taiwan Food & Drug Authority (TFDA), which is considered to be one of the world’s most stringent regulatory agencies, again marking a first time approval for a Bangladeshi company.

Nazmul Hassan, Managing Director of Beximco Pharma, said; “Canada is an important market for Beximco Pharma and this approval marks a significant milestone for the Company, further validating our high standards of quality and compliance practices. This approval builds on our existing presence in key regulated markets and is an important step towards our aspiration to become a global generic drug player.’’

Beximco Pharma is certified by the EU regulatory authority, where the Company has been exporting medicines since 2013, and has received approvals from the relevant authorities in Australia, Latin America, Gulf Nations, and South Africa, among others. In addition, Beximco Pharma has won the National Export Trophy (Gold), the highest national accolade for export, a record four times for its outstanding contribution to the country’s export.

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 861 9151, ext.20080

Daniel Stewart & Company (NOMAD and Broker)
Emma Earl
Paul Shackleton
Tel: +44 (0)20 7776 6550

FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000

Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island, Latin & Central American countries, Middle East, Central Asia, South East Asia, including Singapore, Malaysia, Philippines & Hong Kong, and Europe & Austria.

BEXIMCO PHARMACEUTICALS LTD.

5^th November, 2014

US Ambassador Dan W Mozena visits Beximco Pharma

The US Ambassador to Bangladesh, His Excellency Dan W. Mozena, visited the state-of-the-art manufacturing facilities of Beximco Pharmaceuticals Ltd. (BPL) at Tongi on November 4, 2014 (Tuesday). He was accompanied by Daniel Keen, Economic Commercial Officer and other officials of the Embassy.

US ambassador was welcomed at the plant premises by Nazmul Hassan, MP, Managing Director of BPL. Chief Operating Officer Rabbur Reza and other senior officials from the company were present on this occasion.

Read more...

Open/ Download

Open/ Download

BEXIMCO PHARMACEUTICALS LTD.

July 3, 2014

Beximco Pharma Receives GMP Approval from Taiwan Food and Drug Administration (TFDA) as the First Bangladeshi Company

Beximco Pharmaceuticals Limited (“BPL” or “the Company”), the fast-growing manufacturer of generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids, today announces that it has received GMP (“Good Manufacturing Practices”) accreditation from Taiwan Food and Drug Administration (TFDA) as the first Bangladeshi company. The company has received the approval for its oral solid, Inhaler and sterile eye drop facilities.

Taiwan FDA is considered as one of the most stringent regulatory agencies in the globe and by obtaining the GMP approval Beximco Pharma has added another sterling feather in its cap. This prestigious and valuable achievement opens new marketing opportunity for Beximco Pharma’s products in ASEAN market including Taiwan, which is one of the advanced pharmaceutical markets in Asia. Like several other developed countries, Taiwan is increasingly promoting access to generic drugs which offers opportunities for generic drug companies like Beximco Pharma as until today only a few generic companies have Taiwan FDA approval.

Read more...

Ahmed Sohail Fasiur Rahman, Chairman of Beximco Pharmaceuticals, said: "The Board of Directors recall with appreciation and gratitude Mr. Mahbubul Alam's contribution towards Beximco Pharmaceuticals Ltd during his short tenure as a Non-Executive Independent Director. The Beximco Pharma Family extends their deepest sympathy and sincerest condolences to the bereaved members of his family at his sad demise."

BEXIMCO PHARMACEUTICALS LTD.

14 May, 2014

Beximco Pharma’s Q1’ 14 Results Announced

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), today announces its unaudited financial results for the First quarter ended 31 March 2014 in compliance with the requirements from the Bangladesh SEC

Open/ Download

Open/ Download

The Board of Directors of Beximco Pharmaceuticals Ltd. recalls with appreciation and gratitude his contribution towards the establishment and growth of Beximco Pharmaceuticals Ltd. Beximco Pharma family extends their deepest sympathy and sincerest condolences to the bereaved members of his family at the sad demise.

BEXIMCO PHARMACEUTICALS LTD.

New product launches in 2014

Beximco Pharmaceuticals Ltd. (BPL) has rolled out a good number of products in January 2014, thanks to our R&D and Marketing team. This launching will meet the therapeutic gap needs across Endocrine Disorders,Corticosteroids, Antibiotics, Cardiovascular, Gastrointestinal, Anti-asthma, and Local anesthetic portfolios of BPL.

Endocrine Disorders

Femzole ^®
Letrozole 2.5 mg tablet
Femzole^® is the preparation of letrozole, an oral, anti-estrogen drug that is used for treating postmenopausal women with breast cancer. The growth of some breast cancers in postmenopausal women is promoted by estrogens that circulate in the blood, and the adrenal glands are the main source of these circulating estrogens. Letrozole inhibits the enzyme in the adrenal glands (aromatase) that produces the estrogens, estradiol and estrone. .

Femzole^® is indicated for:

• Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
• Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy
• First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.

Norestin ^®
Norethisterone 5 mg tablet
Norestin® is the preparation of Norethisterone. Norethisterone is a molecule used in some combined oral contraceptive pills, progestogen only pills and is also available as a stand-alone drug. If contraceptive protection is required, additional non hormonal contraceptive methods should be used.

Norestin® is indicated for:

• Spasmodic Dysmenorrhea
• Management of perimenopausal symptoms
• Premenstrual tension
• Management of endometriosis
• For Dysfunctional Uterine Bleeding
• Prophylaxis against recurrent dysfunctional bleeding
• For the treatment of inoperable cancer of the breast
• For postponement of menstruation

Synroid^®
Levothyroxine Sodium 50 mcg tablet
Synroid® contains synthetic Levothyroxine Sodium which is identical to the natural hormone, produced in the thyroid gland. Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone. It is indicated for the following conditions:

• As replacement therapy in hypothyroidism of any etiology.
• For the suppression of Thyroid Stimulating Hormone (TSH) levels in the presence of goiters, nodules and after radiological and/or surgical treatment of thyroid cancer.
• For the suppression of the goitrogenic effects of other drugs such as lithium.
• As a diagnostic aid in suppression tests.

Corticosteroids

Bexipred ®
Prednisolone 20 mg tablet
Prednisolone is a corticosteroid drug with predominant glucocorticoid & low mineralocorticoid activity. It is indicated:

• as  an  anti-inflammatory  or  immunosuppressive  agent  for  certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation
• for the treatment of certain endocrine conditions
• for palliation of certain neoplastic conditions ( Hematologic disorders: Idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, eythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anemia.

Odeson®
Dexamethasone 5 mg tablet
Dexamethasone is a synthetic corticosteroid exhibiting both anti-inflammatory and immuno- suppressant properties. Corticosteroids are hormones produced naturally by the adrenal glands which have many important functions on every organ system.

Indications:

• As an anti-inflammatory medication.  Dexamethasone relieves inflammation in various parts of the body.  It is used specifically to decrease swelling (edema), associated with tumors of the spine and brain, and to treat eye inflammation.
• To treat or prevent allergic reactions.
• As treatment of certain kinds of autoimmune diseases, skin conditions, asthma and other lung conditions.
• As treatment for a variety of cancers, such as leukemia, lymphoma, and multiple myeloma.
• To treat nausea and vomiting associated with some chemotherapy drugs.
• Conditions of adrenal insufficiency (low production of needed steroids produced by the adrenal glands).

Antiemetic

Onsat 4& 8 Oral Soluble Film

Ondensetron 4 mg & 8mg

Onsat® (ondansetron) oral soluble film is the first orally dissolving film introduced by Beximco Pharmaceuticals Ltd. in Bangladesh.  Onsat® offers an innovative and convenient, easy-to-take formulation for patients who have trouble swallowing tablets, while providing the trusted efficacy expected from ondansetron

Onsat® OSF is designed to be applied on top of the tongue where it will dissolve within 20 seconds and then is swallowed with saliva. Onsat® does not require water to aid dissolution or swallowing.
The active ingredient in Onsat® is ondansetron base, the racemic form of ondansetron, and a selective blocking agent of the serotonin 5-HT3 receptor type

Onsat® Oral Soluble Film  is indicated for:

• Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
• Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
• Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to abdomen, or daily fractions to the abdomen.
• Prevention of postoperative nausea and/or vomiting

Oral Antibiotics

Azithrocin® 250

Azithromycin 250 mg Tablet
Azithrocin^® 250 is supplied for oral administration as film-coated tablets containing azithromycin dihydrate equivalent to 250 mg azithromycin. It is an azalide, a subclass of macrolide antibiotics, active against Gram-positive and gram-negative organisms. Azithromycin interferes with ribosome function in susceptible bacteria by inhibiting the translocation of peptide
Azithrocin^® (Azithromycin) is indicated for infections caused by susceptible organisms, in upper respiratory tract infections including sinusitis, pharyngitis and tonsillitis, in lower respiratory tract infections including bronchitis and pneumonia, skin and soft tissue infections, and otitis media. Azithrocin^® is indicated for pelvic inflammatory disease. It is indicated in the treatment of uncomplicated genital infections due to Chlamydia trachomatis. It is a good addition in Azithrocin® family as the tablet can be taken regardless of meal making it an ideal choice for pediatric patients.

Clinacyn^®

Clindamycin 150 & 300 mg Capsule

Clindamycin is a lincosamide antibiotic. Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome. It has activity against Gram-positive aerobes and anaerobes as well as the Gram-negative anaerobes.

Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate.

Gastrointestinal

Frelax ®

Magnesium Hydroxide and Liquid Paraffin Oral Emulsion
Frelax^® Oral Emulsion is a combination of Magnesium Hydroxide and Liquid Paraffin which is recommended for the temporary relief of constipation. Magnesium Hydroxide has an indirect cathartic action, which results from water retention in the stomach lumen due to increased osmotic pressure. Liquid Paraffin acts as a mild laxative by softening stools thus easing defecation.

Frelax^® Oral Emulsion is indicated for Constipation, Hyperacidity with constipation, Anorectal disorder, Post-operative constipation, Constipation associated with chronic cholecystitis, Hernia.

Digecid^® Plus

Megaldrate 480 mg+ Simethicone 20 mg / 5ml suspension
Magaldrate/simethicone suspension is an antacid and antiflatulent combination.  The antacid works by neutralizing stomach acid and increasing the pH of the stomach. The antiflatulent works by breaking up gas bubbles, which makes gas easier to eliminate.
Digecid® Plus is indicated to relieve symptoms of dyspepsia, heartburn, acid indigestion, sour stomach, gastroesophageal reflux and hiatal hernia. It is also prescribed in hyperacidity associated with peptic ulcers, gastritis and esophagitis.  Also indicated for the relief of flatulence, abdominal distension and windy colic. Digecid® Plus suspension is specially formulated with high acid neutralizing capacity (ANC) .

Viscocid ^®

Sodium Alginate 500 mg & Potassium Bicarbonate 100mg / 5ml suspension
Viscocid^® is the combination of Sodium Alginate & Potassium Bicarbonate that relieves the symptoms of reflux such as heartburn. Sodium Alginate is a naturally occurring substance. It reacts with the acid in the stomach to form a gel. Potassium Bicarbonate also reacts with the acid in the stomach to form bubbles of carbon dioxide. These bubbles are trapped by the gel and they allow the gel to float like a raft on top of the stomach contents. The raft prevents acid in the stomach from flowing back into the food pipe.
Viscocid^® suspension is indicated for the treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.

Opton^®

Esomeprazole 20 & 40 mg Delayed Release Capsule
Opton^® capsule is the line extension of Opton brand supplied in delayed-release capsules. Each delayed-release capsule contains 20 mg, or 40 mg of esomeprazole
Opton^® is a proton pump inhibitor indicated for

• Treatment of Gastroesophageal Reflux Disease (GERD)
• Risk Reduction of NSAID-Associated Gastric Ulcer
• H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
• Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.

Antihypertensive

Indelix SR^®

Indepamide1.5 mg Sustained Release Tablet

Indelix^® SR (Indepamide) is an oral antihypertensive which belongs to class of drug called diuretic. It is a prolonged-release film-coated tablet containing indapamide as the active ingredient.  
Indelix^® SR is indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. It is also indicated for the treatment of salt and fluid retention associated with congestive heart failure.

Anti-asthma

Monocast^® 4 Granules

Montelukast 4 mg granules/sachet
Monocast Granules sachet is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes causes narrowing and swelling of airways in the lungs. By blocking leukotrienes montelukast improves asthma symptoms and helps control asthma.

Monocast® 4 Granules is used for the treatment of 6 months to 5 year old patients who are not adequately controlled on their medication and need additional therapy.  Monocat® Granules may also be used as an alternative treatment to inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids. It also helps prevent the narrowing of airways triggered by exercise for patients 2 years of age and older.

Mucomist ^®- DT

Acetylcysteine 600 mg dispersible tablet
Mucomist® DT is the preparation of Acetylcysteine, a derivative of the amino acid, cysteine. Each dispersible tablet contains Acetylcysteine 600 mg. The dispersible tablet formulation ensures optimum stability, rapid dissolution, maximal absorption and high bioavailability. Acetylcysteine has a mucolytic activity through its free sulfhydryl group. It acts directly on the mucoproteins to open the disulfide bonds and thus lowers the viscosity of the mucous and facilitates its removal by the muco-cillary action and expectoration.

Mucomist® DT is indicated for the treatment of abnormal, sticky, or thick mucus secretions in various lung problems (eg, chronic emphysema, bronchitis, asthmatic bronchitis, pneumonia, during anesthesia, following surgery or various lung tests).

Mucomist ® DT should be dissolved in 1/2 glass of water before use (preferably in the evening). The duration of treatment should be 5 to 10 days in the acute phase. It may be continued in the chronic state for up to 6 months or according to the advice of the physician.

Anti-diabetic

Informet ^®LA 750

Metformin Hydrochloride 750 mg extended release tablet
Metformin Hydrochloride belongs to a biguanide class of oral antidiabetic drugs. It decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity. Unlike sulfonylureas, Metformin Hydrochloride does not produce hypoglycemia. It is the drug of first choice in obese patients.

Informet^® LA 750 is a long acting tablet formulation. The usual starting dose is 750 mg once daily with the evening meal. Dosage increase should be made in increments of 750 mg weekly, up to maximum of 1500 mg once daily with the evening meal after consulting with doctor.

16 January 2014

Beximco Pharmaceuticals Ltd.

Appointment of Nominated Adviser

Beximco Pharmaceuticals Limited (“Beximco Pharma”, "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, is pleased to announce that Daniel Stewart & Company plc ("Daniel Stewart") has been appointed as Nominated Adviser to the Company with immediate effect. Daniel Stewart will continue to act as the Company's Sole Broker.

Read more...

BEXIMCO PHARMACEUTICALS LTD.

31 October, 2013

Beximco Pharma’s Q3’ 13 Results Announced

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), today announces its unaudited financial results for the Third quarter ended 31 October 2013 in compliance with the requirements from the Bangladesh SEC

Open/ Download

BEXIMCO PHARMACEUTICALS LTD.

New product launches in 2013

During January to September 2013 Beximco pharma has further extended its product line with 21 new products across therapeutic groups of Cardiovascular, Antibiotics, Antifungal, Vitamins & Mineral supplements, Pain management, Erectile Dysfunction (ED) and Anti-diabetics.

Oral Anti-Diabetics

Diapro^® 30 MR
Gliclazide 30 mg Modified Release Tablet

Diapro^® is an oral blood glucose lowering drug of the sulfonylurea class. Diapro^® is used to treat patients with type 2 diabetes mellitus. The primary mechanism of action of Diapro^® is lowering of blood glucose by stimulating the release of insulin from functioning pancreatic beta cells. In addition, expancreatic effects may also play vital role in the activity of Diapro^®. Administration of Diapro^® can lead to increase sensitivity of peripheral tissues to insulin

Cardiovascular

Metazine^®MR
Trimetazidine Hydrochloride 35 mg Tablet

Metazine^® MR is a Modified Release formulation of mg which is a unique anti-anginal and anti-ischemic agent that exerts anti-ischemic effects without inducing hemodynamic changes and improves the status of ischemic myocardium. Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line anti-anginal therapies.
Metoprol^®- XL
Metoprol 50 & 100 mg Tablet
Metoprolol succinate, is a beta1-selective (cardio selective) adrenoceptor blocking agent, for oral administration, available as extended release tablets. METOPROL-XL has been formulated to provide a controlled and predictable release of Metoprolol for once-daily administration. The tablets comprise a multiple unit system containing Metoprolol succinate in a multitude of controlled release pellets. Each pellet acts as a separate drug delivery unit and is designed to deliver Metoprolol continuously over the dosage interval.

Citicol^®
Citicoline 500 mg/4ml IV/IM Injection
Citicol^® is a psychostimulant/nootropic agent indicated for patients suffering from stroke, age-associated memory impairment (AAMI), head injury, cerebrovascular disorders (disease of the blood vessels supplying the brain). Citicoline is also indicated for cognitive support and support for nerves of the eye.

Erectile Dysfunction

Adafil^®
Tadalafil 10 mg Tablet
Adafil^® contains Tadalafil which is a potent, selective, reversible inhibitor of cyclic Guanosine Monophosphate specific Phosphodiesterase type 5 (PDE5). Adafil^® is indicated in erectile dysfunction (ED).

Antifibrinolytic

Tranexil
Tranexamic Acid 500 mg/5ml Injection
Tranexil^® a antifibrinolytic agent is effective to reverse the effects of streptokinase or other fibrinolytic activity. It may be used for conditions in which bleeding control is required such as after surgery or injury, recurrent nosebleeds or abnormal vaginal bleeding

Vitamins & Minerals Supplements

Calorate®
Calcium Orotate 400 mg Tablet
Calorate is a calcium supplement with a functional amino acid chelating ligand - orotic acid. Orotic acid assists the transport of calcium through cellular membrane structures, thus facilitating the intracellular uptake of calcium, particularly in bone. Calcium Orotate also helps in the maintenance of healthy cartilage. Calorate^® is used to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.
Hemofix^®
Ferrous ascorbate Tablet
Hemofix^® tablet contains ferrous ascorbate 275 mg equivalent to elemental iron 33 mg. Ferrous ascorbate is a synthetic molecule of ascorbic acid and iron. Ascorbic acid plays an important role in the movement of plasma iron to storage depots in tissues. This molecule doesn’t dissociate on entering the GI tract due to the stable chelate of iron with ascorbate. Ascorbate is a reducing agent and prevents oxidation. Hence, it maintains iron in highly soluble ferrous form. All this factors contribute to the highest absorption of ferrous ascorbate. Hemofix^® is indicated in the treatment of iron deficiency anemia

Hemofix^® FZ tablet
Ferrous ascorbate +Folic acid+ Zinc
Hemofix^® FZ is a film coated tablet containing ferrous ascorbate equivalent to elemental iron 48 mg, folic acid 0.5 mg & Zinc Sulfate Monohydrate 61.8 mg equivalent to elemental zinc 22.5 mg. It is indicated on prophylaxis of iron deficiency especially when an inadequate diet calls for supplementary zinc and iron during pregnancy and anemia

Jointec^® Max
Glucosamine + Diacerin Tablet
Jointec^® Max is a combination of Diacerein 50 mg and Glucosamine sulfate 750 mg tablet, which is indicated for the treatment of Osteoarthritis. Diacerein is a new antiinflammatory drug, developed specially for the treatment of Osteoarthritis. Glucosamine Sulfate is a naturally occurring chemical found in the human body

Pain management

Feburic^®
Febuxostat 40 mg Tablet

Feburic^® contains the active ingredient febuxostat, which is a type of medicine called a xanthine oxidase inhibitor. Febuxostat is used to treat gout.
Nervalin^®
Pregabalin 50 & 75 mg Capsule
Nervalin is a modulator of voltage-gated calcium channels, designed to affect neurological transmission in multiple systems. It is specifically indicated for the treatment of neuropathic pain associated with spinal cord injury. It is also indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy, for post herpetic neuralgia, for fibromyalgia, and as an adjunctive therapy for adults with partial onset seizures.

Voligel^®
Diclofenac sodium 50 gm gel
Voligel^® is the unique topical preparation of Diclofenac sodium, methyl salicylate & menthol. It gives instant relief from any kind of muscle & joint pain such as back ache, neck & shoulder pain, joint pain etc. The launching of Voligel^® offers patients a new way to treat daily aches with outstanding safety.

Eye Irrigating Solution

Navsol^® Irrigating Solution
Balanced Salt Solution
Navsol^® Sterile Irrigating Solution is a sterile physiological balanced salt solution of Sodium Chloride (NaCl), Potassium Chloride (KCl), Calcium Chloride Dihydrate (CaCl2•2H2O), Magnesium Chloride Hexahydrate (MgCl2•6H2O), Sodium Acetate Trihydrate (C2H3NaO2•3H2O), and Sodium Citrate Dihydrate (C6H5Na3O7•2H2O). Navsol^® is isotonic to the tissues of the eyes and is indicated as irrigation solution during various surgical procedures of the eyes, ears, nose and/or throat.

Antibiotics

Tyclav^®
Amoxycillin + Clavulanic acid Tablet
Tyclav^® (375 mg, 625 mg and 1 g tablet) is an antibacterial combination consisting of amoxicillin and the beta-lactamase inhibitor, clavulanate potassium. Amoxicillin is a semi-synthetic antibiotic with in vitro bactericidal activity against Gram-positive and Gram-negative bacteria. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins.The formulation of amoxicillin and clavulanic acid in Tyclav protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin.

Antifungal

Omastin^® IV
Fluconazole 2mg/5ml
Omastin injection is used to treat serious fungal or yeast infections, such as vaginal candidiasis, oropharyngeal candidiasis (thrush, oral thrush), esophageal candidiasis (candida esophagitis), other candida infections (including urinary tract infections, peritonitis [inflammation of the lining of the abdomen or stomach], and infections that may occur in different parts of the body), or fungal (cryptococcal) meningitis

Osteoporosis

Calorate Kit
1 tablet of Ibandronic Acid 150 mg+ 60 tablets of Calcium Orotate 400 mg
Beximco Pharmaceuticals Ltd. (BPL) introduced Calorate® Kit for the first time in Bangladesh. Calorate® kit comprises 1 tablet of Ibandronic Acid 150 mg and 60 tablets of Calcium Orotate 400 mg, indicated for the treatment and prevention of osteoporosis. Osteoporosis is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures of the hip, spine and wrist. Osteoporosis is a major cause of mortality and morbidity of post-menopausal women.

Ibandronic acid increases bone mineral density (BMD) and reduce the incidence of vertebral fractures. One tablet of Ibandronic acid 150 mg once monthly on the same date of each month is recommended.
To maximize clinical benefit of Ibandronic acid, two tablets of Calcium orotate 400 mg per day are usually recommended in divided dosage or as directed by physician.

BEXIMCO PHARMACEUTICALS LTD.

August, 2013

Beximco Pharma and its MD win Awards at Asian Brand & Leadership Summit 2013

Beximco Pharmaceuticals Ltd. has won the prestigious Asia's Most Promising Brand award at the Asian Brand & Leadership Summit 2013 held during 26-27 August, 2013 in Dubai.  Beximco Pharma ranked among Top 30 from among 200 emerging brands in Asia. It also received Industry's #1 award in pharma category. Beximco Pharma COO Mr. Rabbur Reza received the award at a gala ceremony held on 27 August in Dubai. Company’s Managing Director, Nazmul Hassan MP received the Asia’s Most Influential Leader award for his outstanding leadership and contribution to business and economic growth in the country as well as in the region.

Read more...

BEXIMCO PHARMACEUTICALS LTD.

30 July, 2013

Beximco Pharma’s Half yearly 2013 Results Announced

Beximco Pharmaceuticals Limited announces its un-audited financial results for the half year ended June 30, 2013 in compliance with the requirements from the Bangladesh SEC

Open/ Download

BEXIMCO PHARMACEUTICALS LTD.

27^th May, 2013

Delegation from United Kingdom Royal College of Defense Studies (RCDS) visited manufacturing facilities of Beximco Pharma

Delegation from United Kingdom Royal College of Defense Studies (RCDS) headed by Air Commodore Steve Abbott and Colonel Darrel Amison, visited the state-of-the-art manufacturing facility of Beximco Pharmaceuticals Ltd. (“BPL” or the “Company”) at Tongi on 26th May 2013, a company statement said today. He was accompanied by Lt. Col. Stuart Cattermull, Defense Advisor of the British High Commission of Dhaka.

Read more...

BEXIMCO PHARMACEUTICALS LTD.

15 May, 2013

Beximco Pharma’s Q1’ 13 Results Announced

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), today announces its unaudited financial results for the First quarter ended 31 March 2013 in compliance with the requirements from the Bangladesh SEC

Open/ Download